Determining First Line Anti-Tuberculosis Drug Resistance among New and Re-treatment Tuberculosis/ Human Immunodeficiency Virus Infected Patients, Nairobi Kenya

Authors

  • Lucy Obonyo Nyang Jomo Kenyatta University of Science and Technology(Itromid)
  • Evans Amukoye
  • Zipporah Ng

Keywords:

Multi drug resistant tuberculosis, New and Retreatment, HIV, Resistance

Abstract

Drug resistant tuberculosis (T.B) is a state when Mycobacterium tuberculosis (MTB) organisms are resistant to antimicrobial agents at the levels attainable in blood and tissue. Scarce data exists on the prevalence of resistance to first line anti-tuberculosis drugs in populations with high rates of tuberculosis and human immunodeficiency virus (H.I.V). Strains of MTB complex from MGIT were subjected to drug susceptibility testing for isoniazid (INH), Rifampicin (R), Streptomycin(S), and Ethambutol (E) using the proportional method on (MGIT). A total of 145 TB patients were enrolled for study. Of the 138 patients who had valid results for analysis, 79(57.2%) were male and 59(42.8%) were female.

Most of the patients (20.3%) were aged between 35-39 years with the lowest proportion (3.6%) being in the younger category <20 years. Among the pulmonary tuberculosis patients 34% were new cases while 66% were retreatment cases. A total of 43(31.2%) strains showed resistance to at least one drug tested, while 112(81.2%) were susceptible. The isolates showed different resistance patterns with mono-resistance in 15(11%) isolates, total multi- drug resistance (MDR) in 6(4.3%) isolates with new and retreatment cases being 0(0.0%) and 6(6.6%) respectively. Mono-resistance was recorded in all four drugs tested. The isolates were resistant to the antibiotics as follows; 16(17.6% and 0(0.0%) were resistant to INH; 9(9.9%) and 0(0.0%) were resistant to R; 10(11.0%) and INH (2.1%) were resistant to E; 7(7.7%) and 0(0.0%) were resistant to S; 6(6.6%) and 0(0.0%) were multi drug resistant among retreatment and new cases respectively. Our study concluded that there were high levels of drug resistance among those previously treated for TB.

Author Biography

Lucy Obonyo Nyang, Jomo Kenyatta University of Science and Technology(Itromid)

Laboratory

Lab Technologist

References

. Bevan, C.D. and Marshal (2009). Tuberculosis the disease (vol.1) Macmillan press. Pp.34-54

. Corbett, E.L. Watt, C.J. Walker, W. Maher, D. William, B.G. (2008). The growing burden of tuberculosis in HIV infected patients: global trends and interactions with the HIV epidemic. International Journal of Tuberculosis and Lung Diseases 163: 1009-1021

. Crofton, J. and Mitchson, D. (2009). Streptomycin resistance in pulmonary tuberculosis. British Medical Journal 27: 1009-1015

. Cliff, A. and Smith, F. (2007). Epidemiology and control of tuberculosis in Western European cities. International Journal of Tuberculosis and Lung Diseases 7: 751-757

. DLTLD (2010). Guidelines for the management of multidrug resistant TB in Kenya, Division of Leprosy, Tuberculosis and Lung Disease, Nairobi.

. Edlin, B.R. Tokars, J.I. Williams, J. Sordillo, E. Ongari, K. Kilburn, J. Castro, K. G. (2009). An outbreak of multi-drug resistant tuberculosis among hospitalized patients with AIDS, British Medical Journal 326:1514-1521.

Ferebee S.H. Comstock, G.W. Hammes, L.M. (2008). A controlled trial of community wide Isoniazid prophylaxis in Alaska. Review on Respiratory Diseases 95:935-943

. Mcshane, H. (2008). Co-infection with HIV and TB: Double trouble. International British Medical Journal 16: (2) 95-100

. Squire, S.B. Harries, A.D. Whitty C.J. (2011). Smear negative pulmonary tuberculosis in a DOTS program: Poor outcome in an area of high HIV sero-prevalence. International Journal of Tuberculosis and Lung Diseases 3:521-543

. World health Organization, (2005). Interim recommendations for the surveillance of drug resistance in tuberculosis

. World Health Organization, (2007). Anti-tuberculosis drug resistance in the world: the WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance

. World Health Organization, (2008a). Anti-tuberculosis drug resistance in the world 4th global report, world Health Organization, Geneva, Switzerland

. World Health Organization, (2008b). Guidelines for the programmatic management of drug resistant tuberculosis: Emergency update 2008, World health Organization, Geneva, Switzerland.

. WHO/GTP, (2010). Surveillance, planning, financing. Geneva, Switzerland.

. World Health Organization, (2009a). Global tuberculosis control- epidemiology, strategy, financing: WHO report 2009, World Health Organization, Geneva, Switzerland.

. World Health Organization (2009b). WHO policy on tuberculosis infection control in health care

. World health Organization, (2010). Multi drug and extensively drug resistant TB: Global report on surveillance and response. Report no. WHO/HTM/ TB/2010.3.Geneva: The Organizations; 2010 Facilities, congregate settings and households, world health Organization, Geneva, Switzerland.

. World health Organization, (2011). Interim recommendations for the surveillance of drug resistance in tuberculosis

. Perpetual, W. N. Samuel, K. Zipporah, N. Gunthuru, R. (2012). Resistance patterns of Mycobacterium Tuberculosis isolates from pulmonary tuberculosis patients in Nairobi. J Infect Dev Ctries 6(1):33-39.

. Uplekar, M.W. Rangan, S. Weiss, M.G. Ogden, J. Burgdorff, M.W. (2008). Attention to gender issues in tuberculosis control. Int. J. Tuberc Lung Dis 5:220-224.

. Jeffrey, K. Hom, B. W. Senica C. Janet, G. Matilda, M. Jenny, A. Rochelle, P. Walensky, E. Losina, Kenneth, A. Freedberg, I. Bassett, V. (2010). Drug resistant tuberculosis among HIV infected patients starting antiretroviral therapy in Durban South Africa .PLos ONE/www.plosone.org volume 7/issue8/e43281.

. Lee, J.H. Chang, J.H. (2008). Drug resistant tuberculosis in tertiary referral teaching hospital in Korea. Korean J Intern Med 16: 173-179

. Chonde, T.M. Basra, D. Mfinanga, S.G. Range, N. Lwilla, F. (2010). National anti-tuberculosis drug resistance study in Tanzania. Int. J. Tuberc Lung Dis, 14(8) P. 967-972

. Hellen, S. Juan, D. Roy, M. Sabine, R. Dennis, F. Ian, S. Darebay, D. Yared, K. Mohammed, A. (2004). Multidrug resistance in Central Asia. Emerg Infec Dis, 10: 1210-1215

. Kassu, D. Daniel, A. Eshatu, L. Mekdes, G.M. Benium, F. (2008). Drug susceptibility of Mycobacterium tuberculosis isolates from smear negative pulmonary tuberculosis patients, Addis Ababa,Ethiopia. Ethiop J. Health Dev 22:212-215

. Van, D. A. Aung K.J. Chowdhury, S. Saba, S. Paukay, A. Ashraf, A. Rigout, L. Fissette, K. Portael, F. (2008). Drug susceptibility of Mycobacterium tuberculosis in rural area of Bangladesh and its relevance to the National treatment regimens. Inter J Tuberc Lung Dis 3:143-148

. Nunes, E.A. Decapitani, E.M. Coelho, E. Panunto, A.C. Joaquim, O.A. Ramos, M.C. (2008). Mycobacterium tuberculosis and non tuberculosis Mycobacterium isolates among patients with recent HIV infection in Mozambique. J Bras Pneumol 34:10

. Magana A.D.N. Pirera, A.J. Senarathe, V. Chandrasekharan, N.V. (2010). Patterns of drug resistance and RFLP analysis of Mycobacterium tuberculosis strains isolated from recurrent tuberculosis patients in Sri- Lanka. South East Asian. J Trop Med Public Health 41:583-589.

. Abate, G. Miorner, H. (2010). Susceptibility of Multidrug resistant strains of Mycobacterium tuberculosis to amoxicillin in combination with clavullanic acid and ethambutol. Journal on Antimicrobial Chemotherapy 42:735-740

. Boehme, C.C. Nicol, M.P. Nabeta, P. Michael, J.S. Gotuzzo, E. (2011). Feasibility diagnostic accuracy and effectiveness of decentralized use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multi drug resistance: a multicentre implementation study. Lancet 377:1495-1505

. Deus, L. Francis, A. Kenneth, M. George, W. K. Willy, W. Rosemary O. Julius, N.K. Ann, A. Anand D. Moses, L. J.( 2012). Anti-tuberculosis drug resistance among new and previously treated sputum smear positive tuberculosis patients in Uganda: Results of the first National survey

. Yoon, C. Cattamanchi, A. Davis, J.L. Worodria, W. Den, B. S. (2012). Impact of Xpert MTB/RIF Testing on Tuberculosis Management and outcome in Hospitalized Patients in Uganda. PLos ONE 7(11).

. Lawn, S.D. Nicol, M.P. (2011). Xpert-MTB/RIF assay; development, evaluation, and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future of Microbiology, 6(9):1067-1082

. Ogaro, T.D Githui, W. Kikuvi, G. Okari, J. Wangui, E. Asiko, V. (2012). Anti- tuberculosis drug resistance in Nairobi, Kenya. African Medical journal of health Sciences, Volume 2, number 1-2

. WHO (2008). Anti-tuberculosis drugs resistance in the world report NO. 4 prevalence and trends Geneva. The WHO /IUATLD global project on anti-tuberculosis drug resistance surveillance.

. Lonnroth, K. Juramillo, E. Williams, B. Dye, C. Raviglione, M. (2009). Drivers of tuberculosis epidemics. The role of risk factors and social determinants. International Journal on Tuberculosis and lung Diseases 8: 345-357

. Rajeswari, R. Chandrasekaran, V. Suhedev, M. Sivasubramaniam, S. Sudha, G.Rehu,G.(2008). Factors associated with patient and health system delays in diagnosis of tuberculosis in South India. International Journal on Tuberculosis and lung Diseases 6: 789-795

Downloads

Published

2015-01-28

How to Cite

Nyang, L. O., Amukoye, E., & Ng, Z. (2015). Determining First Line Anti-Tuberculosis Drug Resistance among New and Re-treatment Tuberculosis/ Human Immunodeficiency Virus Infected Patients, Nairobi Kenya. International Journal of Sciences: Basic and Applied Research (IJSBAR), 19(2), 426–437. Retrieved from https://gssrr.org/index.php/JournalOfBasicAndApplied/article/view/3353

Issue

Vol. 19 No. 2 (2015)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.